Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from Inhibrx Biosciences Inc ( (INBX) ).
On February 23, 2026, Inhibrx Biosciences posted an updated corporate investor presentation outlining its current programs, financial position, and upcoming catalysts, which it plans to use in meetings with the investment community. The materials highlight the firm’s focus on maximizing shareholder value around a key readout for INBRX-106 and a potential future transaction for ozekibart, while emphasizing that any distributed presentation is provided for information purposes and may not be regularly updated.
The presentation describes a strategic pause on potential sale or spin-off options for ozekibart until Phase 2 data from the Hexagon trial of INBRX-106 in first-line head and neck squamous cell carcinoma clarify valuation, underscoring how clinical outcomes could reshape capital allocation and tax planning. It also details a series of anticipated 2026 milestones, including Ewing sarcoma and colorectal cancer data, a planned BLA submission and potential approval for ozekibart in metastatic or unresectable chondrosarcoma, and possible regulatory discussions on accelerated paths in additional indications, signaling a pivotal year for both pipeline advancement and investor expectations.
The most recent analyst rating on (INBX) stock is a Hold with a $86.00 price target. To see the full list of analyst forecasts on Inhibrx Biosciences Inc stock, see the INBX Stock Forecast page.
Spark’s Take on INBX Stock
According to Spark, TipRanks’ AI Analyst, INBX is a Neutral.
The score is held down primarily by weak financial performance (minimal revenue, large losses, and substantial negative operating/free cash flow). Technicals are mixed with soft near-term momentum, and valuation is constrained by negative earnings and no dividend. Offsetting these risks, corporate updates are constructive with positive study results and a clear regulatory/timeline catalyst path into 2026.
To see Spark’s full report on INBX stock, click here.
More about Inhibrx Biosciences Inc
Inhibrx Biosciences Inc. is a clinical-stage biotechnology company focused on discovering and developing biologic treatments for life-threatening conditions, leveraging in-house expertise across discovery, protein engineering, cell biology, translational research, manufacturing, and clinical development. Founded in 2018, the company has advanced multiple product candidates, including ozekibart (INBRX-109) and INBRX-106, and reported having around 110 employees and significant cash resources as of September 30, 2025.
The company’s pipeline includes INBRX-106, a next-generation hexavalent OX40 agonist designed to enhance anti-tumor T cell activity, particularly in combination with PD-1 inhibitors, and ozekibart, which is being studied in several oncology indications such as metastatic or unresectable chondrosarcoma, Ewing sarcoma, and late-line colorectal cancer. Its strategy targets serious oncology markets where improved immunotherapies and targeted biologics could address high unmet medical needs.
Summary: On February 23, 2026, Inhibrx Biosciences posted an updated corporate investor presentation outlining its current programs, financial position, and upcoming catalysts, which it plans to use in meetings with the investment community. The materials highlight the firm’s focus on maximizing shareholder value around a key readout for INBRX-106 and a potential future transaction for ozekibart, while emphasizing that any distributed presentation is provided for information purposes and may not be regularly updated.
The presentation describes a strategic pause on potential sale or spin-off options for ozekibart until Phase 2 data from the Hexagon trial of INBRX-106 in first-line head and neck squamous cell carcinoma clarify valuation, underscoring how clinical outcomes could reshape capital allocation and tax planning. It also details a series of anticipated 2026 milestones, including Ewing sarcoma and colorectal cancer data, a planned BLA submission and potential approval for ozekibart in metastatic or unresectable chondrosarcoma, and possible regulatory discussions on accelerated paths in additional indications, signaling a pivotal year for both pipeline advancement and investor expectations.
MainPoint1: Inhibrx updated investors on its oncology pipeline, finances, and 2026 catalysts.
MainPoint2: The company paused ozekibart deal plans pending key INBRX-106 trial results and milestone data.
Average Trading Volume: 212,724
Technical Sentiment Signal: Buy
Current Market Cap: $1.19B
For an in-depth examination of INBX stock, go to TipRanks’ Overview page.